Advanced non-squamous NSCLC:Tiragolumab+atezo did not improve OS
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Related Articles
Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations
The FDA has granted priority review to sunvozertinib for advanced/metastatic NSCLC with EGFR exon 20 insertion mutations after progression on chemotherapy.
Fill | SSO 2025 Surgical Oncology Bowl
To join a team for the 2025 SurgOnc Bowl, please complete the following questionnaire. For more information and the rules of engagement, please visit this…
The long road to unbiased estimates of pancreatic cancer incidence in the hereditary breast and ovarian cancer syndrome
The determination of unbiased cancer risk estimates in hereditary breast and ovarian cancer syndrome (HBOC) poses several challenges. The article by Katona and colleagues is…
MDS highlights from ASH 2024
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses his key myelodysplastic syndrome (MDS) highlights from this year’s ASH meeting.…
Kim Evaluates New Regimens for EGFR+ Lung Cancer
During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and…
RP1/Nivolumab Earns Priority Review in Anti–PD-1 Failed Advanced Melanoma
RP1 with nivolumab elicited an ORR of 38.7% with an acceptable safety profile in patients with advanced melanoma who progressed on anti–PD-1 therapy.
Immunotherapy Improves Survival in Bladder Cancer | Cancer Today
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
Addition of anthracyclines to chemotherapy improves survival in high-risk breast cancer
SAN ANTONIO — The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with breast cancer, according to data presented at…
Editors’ Selections from Relevant Scientific Publications
Prevention averts death (by Nick Youngson via The Blue Diamond Gallery)Cancer prevention, screening and treatment efforts have averted an estimated 5.94 million deaths in the…
Getting a Second Opinion
Before starting any type of treatment, a patient may consider getting a second opinion–especially if some characteristics of the diagnosis are complicated or uncertain.
